Table 3

Logistic regression model 2 for the testing rate

	ALK		EGFR		PD-L1		ROS1
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Sample type* (ref. biopsy)
Cell block	1.20 (0.79 to 1.83)	0.393	0.94 (0.57 to 1.60)	0.807	0.47 (0.37 to 0.60)	<0.001	0.85 (0.65 to 1.12)	0.242
FNA	0.29 (0.19 to 0.44)	<0.001	3.83 (1.74 to 9.69)	0.002	0.05 (0.03 to 0.09)	<0.001	0.71 (0.47 to 1.08)	0.112
Surgical piece	0.58 (0.41 to 0.82)	0.002	1.02 (0.68 to 1.55)	0.909	0.65 (0.52 to 0.80)	<0.001	1.27 (1.00 to 1.63)	0.051
Others	0.23 (0.16 to 0.33)	<0.001	2.78 (1.50 to 5.55)	0.002	0.27 (0.20 to 0.37)	<0.001	0.80 (056 to 1.13)	0.198
NSCLC-NOS (ref. adenocarcinoma)	0.86 (0.57 to 1.31)	0.477	1.13 (0.67 to 2.00)	0.660	1.40 (1.04 to 1.90)	0.029	0.79 (0.59 to 1.07)	0.128
Testing rate ALK (yes vs no)	–	–	20.61 (13.96 to 31.01)	<0.001	3.61 (2.71 to 4.87)	<0.001	61.50 (36.97 to 111.36)	<0.001
Testing rate EGFR (yes vs no)	24.9 (16.8 to 37.4)	<0.001	–	–	0.12 (0.08 to 0.17)	<0.001	3.07 (1.99 to 4.76)	<0.001
Testing rate PD-L1 (yes vs no)	4.16 (3.07 to 5.69)	<0.001	0.12 (0.08 to 0.17)	<0.001	–	–	2.34 (1.95 to 2.80)	<0.001
Testing rate ROS1 (yes vs no)	72.3 (42.7 to 133.3)	<0.001	3.56 (2.29 to 5.54)	<0.001	2.41 (2.01 to 2.90)	<0.001	–	–
Hosmer-Lemeshow, p value	0.313		<0.001		<0.001		0.234
AUROC (95% CI)	0.93 (0.92 to 0.94)		0.854 (0.825 to 0.884)		0.744 (0.727 to 0.762)		0.793 (0.777 to 0.810)

The results of the Hosmer-Lemeshow test and the AUROC are in italics to differentiate them from the ORs.
*Category ‘others’ includes blood samples.
ALK, anaplastic lymphoma kinase; AUROC, area under receiver operating characteristic curve; EGFR, epidermal growth factor receptor; FNA, fine-needle aspiration; NSCLC-NOS, non-small cell lung cancer–not otherwise specified; PD-L1, programmed death ligand-1; ref., reference; ROS1, c-ros oncogene 1.